Pyrotinib + Placebo Oral Tablet + Trastuzumab + Docetaxel
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-positive Breast Cancer
Conditions
HER2-positive Breast Cancer
Trial Timeline
Jul 24, 2018 → Jan 31, 2024
NCT ID
NCT03588091About Pyrotinib + Placebo Oral Tablet + Trastuzumab + Docetaxel
Pyrotinib + Placebo Oral Tablet + Trastuzumab + Docetaxel is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for HER2-positive Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03588091. Target conditions include HER2-positive Breast Cancer.
What happened to similar drugs?
0 of 14 similar drugs in HER2-positive Breast Cancer were approved
Approved (0) Terminated (0) Active (14)
🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03588091 | Phase 3 | Completed |
Competing Products
20 competing products in HER2-positive Breast Cancer